Canadian private equity firm Brookfield is reportedly considering a €7bn ($7.4bn) takeover bid for Spanish pharmaceutical company Grifols and is completing due diligence on the plasma-based drugmaker, according to a report by El Confidencial.
Brookfield is said to be evaluating a public tender offer at €10.5 per share, slightly below Grifols’ last closing price of €11.125 on Friday.
The Canadian firm previously expressed interest in pursuing the bid in collaboration with the Grifols family, contingent on a favourable outcome from its due diligence process.
Grifols has faced significant headwinds this year, with its market value dropping by approximately 30% since January. The decline has been exacerbated by allegations from short-seller Gotham City Research, which accused the company of inflating its earnings and underreporting its debt—claims strongly denied by Grifols.
Neither Brookfield nor Grifols has issued a statement in response to the report.
